Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse

In the phase 3 OPTIMISMM trial, pomalidomide, bortezomib, and dexamethasone (PVd) demonstrated superior efficacy vs bortezomib and dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma previously treated with lenalidomide, including those refractory to lenalidomide. This analys...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Leukemia
मुख्य लेखकों: Dimopoulos, Meletios, Weisel, Katja, Moreau, Philippe, Anderson, Larry D., White, Darrell, San-Miguel, Jesus, Sonneveld, Pieter, Engelhardt, Monika, Jenner, Matthew, Corso, Alessandro, Dürig, Jan, Pavic, Michel, Salomo, Morten, Casal, Eva, Srinivasan, Shankar, Yu, Xin, Nguyen, Tuong Vi, Biyukov, Tsvetan, Peluso, Teresa, Richardson, Paul
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Nature Publishing Group UK 2020
विषय:
Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC8179841/
https://ncbi.nlm.nih.gov/pubmed/32895455
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41375-020-01021-3
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन